Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases

Current Opinion in Pharmacology

Volumn 40, Issue , 2018, Pages 9-17

  Tan, Wan Shun Daniel ^a   Liao, Wupeng ^a   Zhou, Shuo ^a   Mei, Dan ^a   Wong, Wai Shiu Fred ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RESPIRATORY TRACT AGENT;

ACUTE LUNG INJURY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG EFFICACY; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; HUMAN; LUNG DISEASE; LUNG FIBROSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DRUG DESIGN; HUMANS; LUNG DISEASES; MOLECULAR TARGETED THERAPY; RENIN-ANGIOTENSIN SYSTEM; RESPIRATORY SYSTEM AGENTS; SIGNAL TRANSDUCTION;

EID: 85039418637     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.12.002     Document Type: Review

References (52)

1. Durham, A.L., Caramori, G., Chung, K.F., Adcock, I.M., Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res 167 (2016), 192–203.
2. Spagnolo, P., Wells, A.U., Collard, H.R., Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discov Today 20 (2015), 514–524.
3. Lau, E.M.T., Giannoulatou, E., Celermajer, D.S., Humbert, M., Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 14 (2017), 603–614.
4. Jia, H., Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 46 (2016), 239–248.
5. Kurtz, A., Control of renin synthesis and secretion. Am J Hypertens 25 (2012), 839–847.
6. Balakumar, P., Jagadeesh, G., A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cell Signal 26 (2014), 2147–2160.
7. Kaparianos, A., Argyropoulou, E., Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem 18 (2011), 3506–3515.
8. Shrikrishna, D., Astin, R., Kemp, P.R., Hopkinson, N.S., Renin–angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond) 123 (2012), 487–498.
9. Vinturache, A.E., Smith, F.G., Angiotensin type 1 and type 2 receptors during ontogeny: cardiovascular and renal effects. Vasc Pharmacol 63 (2014), 145–154.
10. Blaes, N., Girolami, J.P., Targeting the ‘Janus face’ of the B2-bradykinin receptor. Expert Opin Ther Targets 17 (2013), 1145–1166.
11. Meng, Y., Yu, C.H., Li, W., Li, T., Luo, W., Huang, S., Wu, P.S., Cai, S.X., Li, X., Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kappaB pathway. Am J Respir Cell Mol Biol 50 (2014), 723–736.
12. Solinski, H.J., Gudermann, T., Breit, A., Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol Rev 66 (2014), 570–597.
13. Guang, C., Phillips, R.D., Jiang, B., Milani, F., Three key proteases — angiotensin-I-converting enzyme (ACE), ACE2 and renin — within and beyond the renin–angiotensin system. Arch Cardiovasc Dis 105 (2012), 373–385.
14. Sakai, H., Nishizawa, Y., Nishimura, A., Chiba, Y., Goto, K., Hanazaki, M., Misawa, M., Angiotensin II induces hyperresponsiveness of bronchial smooth muscle via an activation of p42/44 ERK in rats. Pflugers Arch 460 (2010), 645–655.
15. Myou, S., Fujimura, M., Kurashima, K., Tachibana, H., Watanabe, K., Hirose, T., Type 1 angiotensin II receptor antagonism reduces antigen-induced airway reactions. Am J Respir Crit Care Med 162 (2000), 45–49.
16. Liu, L., Qiu, H.B., Yang, Y., Wang, L., Ding, H.M., Li, H.P., Losartan, an antagonist of AT1 receptor for angiotensin II, attenuates lipopolysaccharide-induced acute lung injury in rat. Arch Biochem Biophys 481 (2009), 131–136.
17. Bullock, G.R., Steyaert, I., Bilbe, G., Carey, R.M., Kips, J., De Paepe, B., Pauwels, R., Praet, M., Siragy, H.M., de Gasparo, M., Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 115 (2001), 117–124.
18. Gard, P.R., Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet 1 (2010), 145–157.
19. Croisant, S., Epidemiology of asthma: prevalence and burden of disease. Adv Exp Med Biol 795 (2014), 17–29.
20. Reddel, H.K., Bateman, E.D., Becker, A., Boulet, L.P., Cruz, A.A., Drazen, J.M., Haahtela, T., Hurd, S.S., Inoue, H., de Jongste, J.C., et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 46 (2015), 622–639.
21. Asher, I., Pearce, N., Global burden of asthma among children. Int J Tuberc Lung Dis 18 (2014), 1269–1278.
22. Magalhaes, G.S., Rodrigues-Machado, M.G., Motta-Santos, D., Silva, A.R., Caliari, M.V., Prata, L.O., Abreu, S.C., Rocco, P.R., Barcelos, L.S., Santos, R.A., et al. Angiotensin-(1–7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol 172 (2015), 2330–2342.
23. Magalhaes, G.S., Rodrigues-Machado, M.G., Motta-Santos, D., Alenina, N., Bader, M., Santos, R.A., Barcelos, L.S., Campagnole-Santos, M.J., Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1–7) Mas receptor knockout mice. Am J Physiol Lung Cell Mol Physiol 311 (2016), L1141–L1148 This study highlights the importance of the Mas receptor in the pathophysiological changes of asthma where an impairment of the Ang (1–7)/Mas receptor pathway resulted in a more severe phenotype.
24. Dhawale, V.S., Amara, V.R., Karpe, P.A., Malek, V., Patel, D., Tikoo, K., Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model. Toxicol Appl Pharmacol 306 (2016), 17–26 This study demonstrates the novel use of DIZE in an experimental rat asthma model to activate ACE2, allowing it to ameliorate asthma progression.
25. Johnson, E.R., Matthay, M.A., Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 23 (2010), 243–252.
26. Bellani, G., Laffey, J.G., Pham, T., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., van Haren, F., Larsson, A., McAuley, D.F., et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315 (2016), 788–800.
27. Yilin, Z., Yandong, N., Faguang, J., Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. Burns 41 (2015), 1468–1477.
28. Schouten, L.R., Helmerhorst, H.J., Wagenaar, G.T., Haltenhof, T., Lutter, R., Roelofs, J.J., van Woensel, J.B., van Kaam, A.H., Bos, A.P., Schultz, M.J., et al. Age-dependent changes in the pulmonary renin–angiotensin system are associated with severity of lung injury in a model of acute lung injury in rats. Crit Care Med 44 (2016), e1226–e1235.
29. Deng, W., Deng, Y., Deng, J., Wang, D.X., Zhang, T., Losartan attenuated lipopolysaccharide-induced lung injury by suppression of lectin-like oxidized low-density lipoprotein receptor-1. Int J Clin Exp Pathol 8 (2015), 15670–15676.
30. Khan, A., Benthin, C., Zeno, B., Albertson, T.E., Boyd, J., Christie, J.D., Hall, R., Poirier, G., Ronco, J.J., Tidswell, M., et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care, 21, 2017, 234 This phase II trial highlights the potential of recombinant human ACE2 (GSK2586881) as a therapy for acute lung injury, where it was well-tolerated and had target engagement.
31. Zambelli, V., Bellani, G., Borsa, R., Pozzi, F., Grassi, A., Scanziani, M., Castiglioni, V., Masson, S., Decio, A., Laffey, J.G., et al. Angiotensin-(1–7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. Intensive Care Med Exp, 3, 2015, 44.
32. Klein, N., Gembardt, F., Supe, S., Kaestle, S.M., Nickles, H., Erfinanda, L., Lei, X., Yin, J., Wang, L., Mertens, M., et al. Angiotensin-(1–7) protects from experimental acute lung injury. Crit Care Med 41 (2013), e334–e343.
33. Liu, Q., Du, J., Yu, X., Xu, J., Huang, F., Li, X., Zhang, C., Li, X., Chang, J., Shang, D., et al. miRNA-200c-3p is crucial in acute respiratory distress syndrome. Cell Discov, 3, 2017, 17021.
34. Wright, J.L., Cosio, M., Churg, A., Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 295 (2008), L1–L15.
35. Adeloye, D., Chua, S., Lee, C., Basquill, C., Papana, A., Theodoratou, E., Nair, H., Gasevic, D., Sridhar, D., Campbell, H., et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5, 2015, 020415.
36. Ayada, C., Toru, U., Genc, O., Sahin, S., Turgut, S., Turgut, G., Angiotensinogen gene M235T and angiotensin II-type 1 receptor gene A/C1166 polymorphisms in chronic obstructive pulmonary disease. Int J Clin Exp Med 8 (2015), 4521–4526.
37. Curtis, K.J., Meyrick, V.M., Mehta, B., Haji, G.S., Li, K., Montgomery, H., Man, W.D., Polkey, M.I., Hopkinson, N.S., Angiotensin-converting enzyme inhibition as an adjunct to pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 194 (2016), 1349–1357.
38. Paulin, P., Maritano Furcada, J., Ungaro, C.M., Bendelman, G., Waisman, G.D., Castro, H.M., Giunta, D.H., Ferreyro, B.L., Effect of angiotensin 2 receptor blockers on chronic obstructive lung disease mortality: a retrospective cohort study. Pulm Pharmacol Ther 44 (2017), 78–82.
39. Borie, R., Justet, A., Beltramo, G., Manali, E.D., Pradere, P., Spagnolo, P., Crestani, B., Pharmacological management of IPF. Respirology 21 (2016), 615–625.
40. Wang, J., Chen, L., Chen, B., Meliton, A., Liu, S.Q., Shi, Y., Liu, T., Deb, D.K., Solway, J., Li, Y.C., Chronic activation of the renin–angiotensin system induces lung fibrosis. Sci Rep, 5, 2015, 15561.
41. Asker, S.A., Mazroa, S.A., Boshra, V., Hassan, A.M., Biochemical and histological impact of direct renin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced pulmonary fibrosis in adult mice. Tissue Cell 47 (2015), 373–381.
42. Wang, L., Wang, Y., Yang, T., Guo, Y., Sun, T., Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice. Cell Physiol Biochem 36 (2015), 697–711.
43. Zhou, J.P., Tang, W., Feng, Y., Li, N., Gu, C.J., Li, Q.Y., Wan, H.Y., Angiotensin-(1–7) decreases the expression of collagen I via TGF-beta1/Smad2/3 and subsequently inhibits fibroblast-myofibroblast transition. Clin Sci (Lond) 130 (2016), 1983–1991.
44. Hampl, V., Herget, J., Bibova, J., Banasova, A., Huskova, Z., Vanourkova, Z., Jichova, S., Kujal, P., Vernerova, Z., Sadowski, J., et al. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1–7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res 64 (2015), 25–38.
45. Yuan, Y.M., Luo, L., Guo, Z., Yang, M., Ye, R.S., Luo, C., Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats. J Renin Angiotensin Aldosterone Syst 16 (2015), 249–253.
46. Breitling, S., Krauszman, A., Parihar, R., Walther, T., Friedberg, M.K., Kuebler, W.M., Dose-dependent, therapeutic potential of angiotensin-(1–7) for the treatment of pulmonary arterial hypertension. Pulm Circ 5 (2015), 649–657.
47. Bruce, E., Shenoy, V., Rathinasabapathy, A., Espejo, A., Horowitz, A., Oswalt, A., Francis, J., Nair, A., Unger, T., Raizada, M.K., et al. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharmacol 172 (2015), 2219–2231.
48. Velkoska, E., Patel, S.K., Burrell, L.M., Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr Opin Nephrol Hypertens 25 (2016), 384–395 This review summarizes the recent findings related to ACE2 and DIZE, highlighting their potential for novel therapeutic approaches and the need for further investigation on the mechanism and toxicity of DIZE.
49. Lee, S., Evans, M.A., Chu, H.X., Kim, H.A., Widdop, R.E., Drummond, G.R., Sobey, C.G., Effect of a selective Mas receptor agonist in cerebral ischemia in vitro and in vivo. PLOS ONE, 10, 2015, e0142087.
50. Danilov, S.M., Tovsky, S.I., Schwartz, D.E., Dull, R.O., ACE phenotyping as a guide toward personalized therapy with ACE inhibitors. J Cardiovasc Pharmacol Ther 22 (2017), 374–386 As initial blood ACE level does not provide a valid prediction to effective drop in blood pressure, this study advocates the use of ACE phenotyping including ACE plasma level, activity, conformation and degree of ACE inhibition to identify resistance towards ACE inhibitors. This allows for personalized therapy and monitoring of compliance.
51. Lowenstein, P.R., Castro, M.G., Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?. Curr Gene Ther 9 (2009), 368–374.
52. Mahmood, J., Jelveh, S., Zaidi, A., Doctrow, S.R., Medhora, M., Hill, R.P., Targeting the renin–angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage. Int J Radiat Oncol Biol Phys 89 (2014), 722–728.